Table 1.
Characteristics of men with adverse pathologic features at prostatectomy who were censored or alive at 10 yr compared with those who died of prostate cancer within 10 yr of surgery
| Variable | No PCSM at ≥10 yr (n = 449) |
PCSM in ≤10 yr (n = 112) |
p valuea |
|---|---|---|---|
|
| |||
| Age, median (IQR) | 62 (57–67) | 61 (57–66) | 0.6 |
|
| |||
| PSA, n (%) | 0.6 | ||
| <10 | 252 (56) | 57 (51) | |
| 10–20 | 124 (28) | 33 (29) | |
| >20 | 73 (16) | 22(20) | |
|
| |||
| RP Gleason, n (%) | <0.001 | ||
| ≤6 | 39 (9) | 0 (0) | |
| 7 | 285 (63) | 32 (29) | |
| 8–10 | 125 (28) | 80 (71) | |
|
| |||
| RP Stage, n (%) | <0.001 | ||
| OC | 168 (37) | 17 (15) | |
| EPE | 147 (33) | 28 (25) | |
| SVI | 87 (19) | 38 (34) | |
| LN | 47 (10) | 29(26) | |
|
| |||
| Surgical margins, n (%) | 0.7 | ||
| Negative | 234 (52) | 61 (54) | |
| Positive | 215 (48) | 51 (46) | |
|
| |||
| CAPRA-S, n (%) | <0.001 | ||
| <3 | 103 (23) | 5 (5) | |
| 3–5 | 200(45) | 36 (32) | |
| >5 | 146 (33) | 71 (63) | |
|
| |||
| GC, n (%) | <0.001 | ||
| <0.45 | 289(64) | 38 (34) | |
| 0.45–0.6 | 84 (19) | 13 (12) | |
| >0.6 | 76 (17) | 61 (54) | |
|
| |||
| Adjuvant ADT or RT, n (%) | <0.001 | ||
| No | 395 (88) | 80 (71) | |
| Yes | 54 (12) | 32 (29) | |
ADT = androgen deprivation therapy; CAPRA-S = Cancer of the Prostate Risk Assessment Postsurgical; EPE = extraprostatic extension; GC = Decipher genomic classifier; IQR = interquartile range; LNI = lymph node involvement; OC = organ confined; PCSM = prostate cancer-specific mortality; PSA = prostate-specific antigen; RP = radical prostatectomy; RT = radiation therapy; SVI = seminal vesicle involvement.
a
Wilcoxon rank sum, Pearson chi-square, or Mantel-Haenszel chi-square test.